1
|
Ujiantari NSO, Ham S, Nagiri C, Shihoya W, Nureki O, Hutchinson D, Schuster D. Pharmacophore-guided Virtual Screening to Identify New β3-Adrenergic Receptor Agonists. Mol Inform 2021; 41:e2100223. [PMID: 34963040 PMCID: PMC9400856 DOI: 10.1002/minf.202100223] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 12/18/2021] [Indexed: 11/21/2022]
Abstract
The β3‐adrenergic receptor (β3‐AR) is found in several tissues such as adipose tissue and urinary bladder. It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation. Two β3‐AR agonists are used clinically: mirabegron 1 and vibegron 2, which are indicated for overactive bladder syndrome. However, these drugs show adverse effects, including increased blood pressure in mirabegron patients. Hence, new β3‐AR agonists are needed as starting points for drug development. Previous pharmacophore modeling studies of the β3‐AR did not involve experimental in vitro validation. Therefore, this study aimed to conduct prospective virtual screening and confirm the biological activity of virtual hits. Ligand‐based pharmacophore modeling was performed since no 3D structure of human β3‐AR is yet available. A dataset consisting of β3‐AR agonists was prepared to build and validate the pharmacophore models. The best model was employed for prospective virtual screening, followed by physicochemical property filtering and a docking evaluation. To confirm the activity of the virtual hits, an in vitro assay was conducted, measuring cAMP levels at the cloned β3‐AR. Out of 35 tested compounds, 4 compounds were active in CHO−K1 cells expressing the human β3‐AR, and 8 compounds were active in CHO−K1 cells expressing the mouse β3‐AR.
Collapse
|
2
|
Enantioselective Chromatographic Separation and Lipase Catalyzed Asymmetric Resolution of Biologically Important Chiral Amines. SEPARATIONS 2021. [DOI: 10.3390/separations8100165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Cyanoacetamides are vital synthons in synthetic organic chemistry. However, methods to enantiopure cyanoacetamides have not yet been well explored. In this work, the preparation of cyanoacetamide synthons RS-(1a–4a) or methoxyacetamides RS-(1b–4b) in enantiopure/enriched form was investigated. Compounds S-1, S-2, R-1b, R-1a, andR-2b were prepared in enantiopure form (ee > 99%) while compounds S-4, R-2a, and R-4a were achieved in ee 9%, 80%, and 76%, respectively. Many baselines enantioselective HPLC separations of amines 1–4, their cyanoacetamides (1a–4a), and methoxyacetamides (1b–4b) were achieved by utilizing diverse mobile-phase compositions and two cellulose-based CSPs (ODH® and LUX-3® columns). Such enantioselective HPLC separations were used to monitor the lipase-catalyzed kinetic resolution of amines RS-(1–4).
Collapse
|
3
|
Fricke J, Sherwood A, Kargbo R, Orry A, Blei F, Naschberger A, Rupp B, Hoffmeister D. Enzymatic Route toward 6‐Methylated Baeocystin and Psilocybin. Chembiochem 2019; 20:2824-2829. [DOI: 10.1002/cbic.201900358] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Indexed: 12/23/2022]
Affiliation(s)
- Janis Fricke
- Department Pharmaceutical Microbiology at the Hans Knöll InstituteFriedrich-Schiller-Universität Beutenbergstrasse 11a 07745 Jena Germany
| | | | - Robert Kargbo
- The Usona Institute 2800 Woods Hollow Road Madison WI 53711 USA
| | - Andrew Orry
- Molsoft L.L.C. 11199 Sorrento Valley Road San Diego CA 92121 USA
| | - Felix Blei
- Department Pharmaceutical Microbiology at the Hans Knöll InstituteFriedrich-Schiller-Universität Beutenbergstrasse 11a 07745 Jena Germany
| | - Andreas Naschberger
- Department of Genetic EpidemiologyMedizinische Universität Innsbruck Schöpfstrasse 41 6020 Innsbruck Austria
| | - Bernhard Rupp
- Department of Genetic EpidemiologyMedizinische Universität Innsbruck Schöpfstrasse 41 6020 Innsbruck Austria
- Hofkristallamt 991 Audrey Place Vista CA 92084 USA
| | - Dirk Hoffmeister
- Department Pharmaceutical Microbiology at the Hans Knöll InstituteFriedrich-Schiller-Universität Beutenbergstrasse 11a 07745 Jena Germany
| |
Collapse
|
4
|
Gabrielli S, Chiurchiù E, Palmieri A. β-Nitroacrylates: A Versatile and Growing Class of Functionalized Nitroalkenes. Adv Synth Catal 2018. [DOI: 10.1002/adsc.201800709] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Serena Gabrielli
- Green Chemistry Group, School of Sciences and Technology, Chemistry Division; University of Camerino; Via S. Agostino no. 1 62032 Camerino (MC Italy
| | - Elena Chiurchiù
- Green Chemistry Group, School of Sciences and Technology, Chemistry Division; University of Camerino; Via S. Agostino no. 1 62032 Camerino (MC Italy
| | - Alessandro Palmieri
- Green Chemistry Group, School of Sciences and Technology, Chemistry Division; University of Camerino; Via S. Agostino no. 1 62032 Camerino (MC Italy
| |
Collapse
|
5
|
2D-QSAR and 3D-QSAR/CoMSIA Studies on a Series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-Phenylethan-1-ol with Human β₃-Adrenergic Activity. Molecules 2017; 22:molecules22030404. [PMID: 28273884 PMCID: PMC6155312 DOI: 10.3390/molecules22030404] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 02/28/2017] [Accepted: 03/02/2017] [Indexed: 11/17/2022] Open
Abstract
The β₃ adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only available drug on the market that targets this receptor approved for the treatment of overactive bladder. However, the FDA (Food and Drug Administration) in USA and the MHRA (Medicines and Healthcare products Regulatory Agency) in UK have made reports of potentially life-threatening side effects associated with the administration of Mirabegron, casting doubts on the continuity of this compound. Therefore, it is of utmost importance to gather information for the rational design and synthesis of new β₃ adrenergic ligands. Herein, we present the first combined 2D-QSAR (two-dimensional Quantitative Structure-Activity Relationship) and 3D-QSAR/CoMSIA (three-dimensional Quantitative Structure-Activity Relationship/Comparative Molecular Similarity Index Analysis) study on a series of potent β₃ adrenergic agonists of indole-alkylamine structure. We found a series of changes that can be made in the steric, hydrogen-bond donor and acceptor, lipophilicity and molar refractivity properties of the compounds to generate new promising molecules. Finally, based on our analysis, a summary and a regiospecific description of the requirements for improving β₃ adrenergic activity is given.
Collapse
|
6
|
Lancianesi S, Palmieri A, Petrini M. Synthetic Approaches to 3-(2-Nitroalkyl) Indoles and Their Use to Access Tryptamines and Related Bioactive Compounds. Chem Rev 2014; 114:7108-49. [DOI: 10.1021/cr400676v] [Citation(s) in RCA: 238] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Stefano Lancianesi
- School
of Science and Technology,
Chemistry Division, Università di Camerino, via S. Agostino,
1, I-62032 Camerino, Italy
| | - Alessandro Palmieri
- School
of Science and Technology,
Chemistry Division, Università di Camerino, via S. Agostino,
1, I-62032 Camerino, Italy
| | - Marino Petrini
- School
of Science and Technology,
Chemistry Division, Università di Camerino, via S. Agostino,
1, I-62032 Camerino, Italy
| |
Collapse
|
7
|
Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, Bansal A, Brown PN, Chen AS, Dingley KH, Di Salvo J, Fitzmaurice A, Gichuru LN, Hurley AL, Jochnowitz N, Miller RR, Mistry S, Nagabukuro H, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Struthers M, Weber AE, Edmondson SD. Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β3Adrenergic Receptor Agonists for the Treatment of Overactive Bladder. J Med Chem 2014; 57:1437-53. [DOI: 10.1021/jm4017224] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Christopher R. Moyes
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Richard Berger
- Early Development and Discovery Sciences, Merck and Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Stephen D. Goble
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Bart Harper
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Dong-Ming Shen
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Liping Wang
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Alka Bansal
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Patricia N. Brown
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Airu S. Chen
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Karen H. Dingley
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jerry Di Salvo
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Aileen Fitzmaurice
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Loise N. Gichuru
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Amanda L. Hurley
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Nina Jochnowitz
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Randall R. Miller
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Shruty Mistry
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Hiroshi Nagabukuro
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Gino M. Salituro
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Anthony Sanfiz
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Andra S. Stevenson
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Katherine Villa
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Beata Zamlynny
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Mary Struthers
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ann E. Weber
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Scott D. Edmondson
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
8
|
Johansson H, Jørgensen TB, Gloriam DE, Bräuner-Osborne H, Pedersen DS. 3-Substituted 2-phenyl-indoles: privileged structures for medicinal chemistry. RSC Adv 2013. [DOI: 10.1039/c2ra21902f] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
9
|
Baggett AW, Cournia Z, Han MS, Patargias G, Glass AC, Liu SY, Nolen BJ. Structural characterization and computer-aided optimization of a small-molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton. ChemMedChem 2012; 7:1286-94. [PMID: 22623398 PMCID: PMC3531959 DOI: 10.1002/cmdc.201200104] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Revised: 05/02/2012] [Indexed: 11/06/2022]
Abstract
CK-666 (1) is a recently discovered small-molecule inhibitor of the actin-related protein 2/3 (Arp2/3) complex, a key actin cytoskeleton regulator with roles in bacterial pathogenesis and cancer cell motility. Although 1 is commercially available, the crystal structure of Arp2/3 complex with 1 bound has not been reported, making its mechanism of action uncertain. Furthermore, its relatively low potency increases its potential for off-target effects in vivo, complicating interpretation of its influence in cell biological studies and precluding its clinical use. Herein we report the crystal structure of 1 bound to Arp2/3 complex, which reveals that 1 binds between the Arp2 and Arp3 subunits to stabilize the inactive conformation of the complex. Based on the crystal structure, we used computational docking and free-energy perturbation calculations of monosubstituted derivatives of 1 to guide optimization efforts. Biochemical assays of ten newly synthesized compounds led to the identification of compound 2, which exhibits a threefold increase in inhibitory activity in vitro relative to 1. In addition, our computational analyses unveiled a surface groove at the interface of the Arp2 and Arp3 subunits that can be exploited for additional structure-based optimization.
Collapse
Affiliation(s)
- Andrew W. Baggett
- Department of Chemistry, University of Oregon, Eugene, OR 97403-1253, United States Tel. 541-346-7412, Fax 541-346-5891
| | - Zoe Cournia
- Biomedical Research Foundation, Academy of Athens, 4 Soranou Ephessiou, 115 27 Athens, Greece
| | - Min Suk Han
- Department of Chemistry, University of Oregon, Eugene, OR 97403-1253, United States Tel. 541-346-7412, Fax 541-346-5891
| | - George Patargias
- Biomedical Research Foundation, Academy of Athens, 4 Soranou Ephessiou, 115 27 Athens, Greece
| | - Adam C. Glass
- Department of Chemistry, University of Oregon, Eugene, OR 97403-1253, United States Tel. 541-346-7412, Fax 541-346-5891
| | - Shih-Yuan Liu
- Department of Chemistry, University of Oregon, Eugene, OR 97403-1253, United States Tel. 541-346-7412, Fax 541-346-5891
| | - Brad J. Nolen
- Department of Chemistry, University of Oregon, Eugene, OR 97403-1253, United States Tel. 541-346-7412, Fax 541-346-5891
| |
Collapse
|
10
|
Efficient Synthesis of (R)-2-Chloro-1-(3-chlorophenyl)ethanol by Permeabilized Whole Cells of Candida ontarioensis. CHINESE JOURNAL OF CATALYSIS 2012. [DOI: 10.1016/s1872-2067(11)60363-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
11
|
Arai T, Awata A, Wasai M, Yokoyama N, Masu H. Catalytic Asymmetric Friedel–Crafts/Protonation of Nitroalkenes and N-Heteroaromatics. J Org Chem 2011; 76:5450-6. [DOI: 10.1021/jo200546a] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Takayoshi Arai
- Department of Chemistry, Graduate School of Science, and ‡Chemical Analysis Center, Chiba University, Inage, Chiba 263-8522, Japan
| | - Atsuko Awata
- Department of Chemistry, Graduate School of Science, and ‡Chemical Analysis Center, Chiba University, Inage, Chiba 263-8522, Japan
| | - Makiko Wasai
- Department of Chemistry, Graduate School of Science, and ‡Chemical Analysis Center, Chiba University, Inage, Chiba 263-8522, Japan
| | - Naota Yokoyama
- Department of Chemistry, Graduate School of Science, and ‡Chemical Analysis Center, Chiba University, Inage, Chiba 263-8522, Japan
| | - Hyuma Masu
- Department of Chemistry, Graduate School of Science, and ‡Chemical Analysis Center, Chiba University, Inage, Chiba 263-8522, Japan
| |
Collapse
|
12
|
Roy KK, Saxena AK. Structural Basis for the β-Adrenergic Receptor Subtype Selectivity of the Representative Agonists and Antagonists. J Chem Inf Model 2011; 51:1405-22. [DOI: 10.1021/ci2000874] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Kuldeep K. Roy
- Division of Medicinal and Process Chemistry, Central Drug Research Institute, CSIR, Lucknow 226 001, India
| | - Anil K. Saxena
- Division of Medicinal and Process Chemistry, Central Drug Research Institute, CSIR, Lucknow 226 001, India
| |
Collapse
|
13
|
Perrone MG, Scilimati A. β3-Adrenoceptor ligand development history through patent review. Expert Opin Ther Pat 2011; 21:505-36. [DOI: 10.1517/13543776.2011.561316] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Grazia Perrone M, Scilimati A. β(3)-Adrenoceptor agonists and (antagonists as) inverse agonists history, perspective, constitutive activity, and stereospecific binding. Methods Enzymol 2011; 484:197-230. [PMID: 21036234 DOI: 10.1016/b978-0-12-381298-8.00011-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
β(3)-Adrenergic receptor (β(3)-AR) is expressed in several tissues and is considered a drug target for the treatment of several pathologies such as obesity, type 2 diabetes, cachexia, metabolic syndrome, heart failure, anxiety and depressive disorders, preterm labor, overactive bladder, control colon motility, and of coadjuvants in colon cancer therapy. It is a seven-transmembrane domain (7TD) G-protein coupled receptor and is usually coupled to a Gs-protein (Gi-protein in very few cases), and its stimulation increases the production of cAMP. A lot of β(3)-AR agonists have been uncovered and extensively characterized. Conversely, very little is known about β(3)-AR inverse agonists that would suppress the agonist-independent activity (constitutive activity) of the receptor by stabilizing it in its inactive state. This chapter attempts to outline (a) the importance of the β(3)-AR as a therapeutic target through the disquisition of its role in human health (physiology) and disease (pathology); (b) the description of β(3)-AR structure [amino acid sequence and 7TD organization]; (c) the medicinal chemistry of β(3)-AR: 7TD amino acid-ligand specific interactions, β-adrenoreceptor subtype selectivity, stereospecific interactions and biological activity relationships, inverse agonism and blockage of β(3)-adrenoceptor constitutive activity; and (d) β(3)-AR inverse agonists. The detailed procedure to prepare and assess the biological activity/selectivity of the more potent and selective β(3)-AR inverse agonists (SP-1e and SP-1g) up to now known is also described.
Collapse
|
15
|
Rodríguez-Mata M, Gotor-Fernández V, González-Sabín J, Rebolledo F, Gotor V. Straightforward preparation of biologically active 1-aryl- and 1-heteroarylpropan-2-amines in enantioenriched form. Org Biomol Chem 2011; 9:2274-8. [DOI: 10.1039/c0ob00800a] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
16
|
Yeung BKS, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 2010; 53:5155-64. [PMID: 20568778 PMCID: PMC6996867 DOI: 10.1021/jm100410f] [Citation(s) in RCA: 318] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
![]()
The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described. Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM. Structure−activity relationships for the optimization of 1 to compound 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented. Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.
Collapse
Affiliation(s)
- Bryan K S Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01 Chromos, Singapore 138670.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kotik M, Štěpánek V, Grulich M, Kyslík P, Archelas A. Access to enantiopure aromatic epoxides and diols using epoxide hydrolases derived from total biofilter DNA. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.molcatb.2010.01.016] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Perrone MG, Bleve L, Santandrea E, Vitale P, Niso M, Scilimati A. The tertiary amine nitrogen atom of piperazine sulfonamides as a novel determinant of potent and selective beta3-adrenoceptor agonists. ChemMedChem 2010; 4:2080-97. [PMID: 19882697 DOI: 10.1002/cmdc.200900292] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Novel compounds were prepared in fair to good yields as human beta(3)-adrenoceptor (beta(3)-AR) agonists. In particular, aryloxypropanolamines 7 a-d (EC(50)=0.57-2.1 nM) and arylethanolamines 12 a,b,e (EC(50)=6.38-19.4 nM) were designed to explore the effects of modifications at the right-hand side of these molecules on their activity as beta(3)-AR agonists. Piperidine sulfonamides 15 a-c, e-g (EC(50)=6.1-36.2 nM) and piperazine sulfonamide derivatives 20-29 (EC(50)=1.79-49.3 nM) were examined as compounds bearing a non-aromatic linker on the right- and left-hand sides of the molecules. Some piperazine sulfonamides were found to be potent and selective beta(3)-AR agonists, even if the amine nitrogen atom is tertiary and not secondary, as is the case for all beta(3)-AR agonists reported so far. (S)-3-{4-{N-{4-{2-[2-Hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl}phenyl}sulfamoyl}phenoxy}propanoic acid (7 d; EC(50)=0.57 nM), (R)-N-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenyl}-4-(3-octylureido)benzenesulfonamide (12 e; EC(50)=6.38 nM), (R)-2-[1-(4-methoxyphenylsulfonyl)piperidin-4-ylamino]-1-phenylethanol (15 f; EC(50)=6.1 nM), and (S)-4-{2-hydroxy-3-[4-(4-methoxyphenylsulfonyl)piperazin-1-yl]propoxy}phenol (25; EC(50)=1.79 nM) were found to be the most potent beta(3)-AR agonists of the aryloxypropanolamine, arylethanolamine, piperidine sulfonamide, and piperazine sulfonamide classes, respectively. The two most potent compounds were identified as possible candidates for further development of beta(3)-AR agonists useful in the treatment of beta(3)-AR-mediated pathological conditions.
Collapse
Affiliation(s)
- Maria Grazia Perrone
- Dipartimento Farmaco-Chimico, Università degli Studi di Bari A. Moro, Via Orabona 4, 70125 Bari, Italy
| | | | | | | | | | | |
Collapse
|
19
|
Senthil Kumar P, Bharatam PV. Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists. Med Chem Res 2009; 19:1121-1140. [PMID: 21170122 PMCID: PMC2988205 DOI: 10.1007/s00044-009-9257-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Accepted: 09/02/2009] [Indexed: 11/15/2022]
Abstract
A quantitative structure–activity relationship study of tryptamine-based derivatives of β1-, β2-, and β3-adrenoceptor agonists was conducted using comparative molecular field analysis (CoMFA). Correlation coefficients (cross-validated r2) of 0.578, 0.595, and 0.558 were obtained for the three subtypes, respectively, in three different CoMFA models. All three CoMFA models have different steric and electrostatic contributions, implying different requirements inside the binding cavity. The CoMFA coefficient contour plots of the three models and comparisons among these plots provide clues regarding the main chemical features responsible for the biological activity variations and also result in predictions which correlate very well with the observed biological activity. Based on the analysis, a summary regeospecific description of the requirements for improving β-adrenoceptor subtype selectivity is given.
Collapse
Affiliation(s)
- P Senthil Kumar
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, (NIPER), Sector 67, S. A. S. Nagar, Mohali, 160 062 India
| | | |
Collapse
|
20
|
Lin H, Chen YZ, Xu XY, Xia SW, Wang LX. Preparation of key intermediates of adrenergic receptor agonists: Highly enantioselective production of (R)-α-halohydrins with Saccharomyces cerevisiae CGMCC 2.396. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/j.molcatb.2008.06.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Perrone MG, Santandrea E, Bleve L, Vitale P, Colabufo NA, Jockers R, Milazzo FM, Sciarroni AF, Scilimati A. Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists. Bioorg Med Chem 2007; 16:2473-88. [PMID: 18083578 DOI: 10.1016/j.bmc.2007.11.060] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2007] [Revised: 11/13/2007] [Accepted: 11/21/2007] [Indexed: 11/29/2022]
Abstract
Since it is widely distributed into the body, beta(3)-adrenoceptor is becoming an attractive target for the treatment of several pathologies such as obesity, type 2 diabetes, metabolic syndrome, cachexia, overactive bladder, ulcero-inflammatory disorder of the gut, preterm labour, anxiety and depressive disorders, and heart failure. New compounds belonging to the class of arylethanolamines bearing one or two stereogenic centres were prepared in good yields as racemates and optically active forms. They were, then, evaluated for their intrinsic activity towards beta(3)-adrenoceptor and their affinity for beta(1)- and beta(2)-adrenergic receptors. Stereochemical features were found to play a crucial role in determining the behaviour of such compounds. In particular, alpha-racemic, (alphaR)- and (alphaS)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}-2- methylpropanoic acid, (alpha-rac, beta-rac)-, (alphaR, betaS)- and (alphaR, betaR)- 2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid were found to be endowed with beta(3)-adrenoceptor agonistic activity. Whereas, (alphaS, betaS)- and (alphaS, betaR)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid behaved as beta(3)-adrenoceptor inverse agonists. Such compounds showed no affinity for beta(1)- and beta(2)-adrenergic receptor, respectively. Thus, resulting highly selective beta(3)-adrenoceptor ligands.
Collapse
Affiliation(s)
- Maria Grazia Perrone
- Dipartimento Farmaco-Chimico, Università di Bari, Via E.Orabona 4, 70125 Bari, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mateo C, Fernandez-Lafuente R, Archelas A, Guisan JM, Furstoss R. Preparation of a very stable immobilized Solanum tuberosum epoxide hydrolase. ACTA ACUST UNITED AC 2007. [DOI: 10.1016/j.tetasy.2007.05.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Ikunaka M, Kato S, Sugimori D, Yamada Y. N,N-Diethyl-(R)-[3-(2-aminopropyl)-1H-indol-7-yloxy]acetamide: Its Process Chemistry Ranging from Enantiocontrolled Construction of the Chiral Amine Side Chain to Regioselective Functionalization of the Aromatic Starting Materials. Org Process Res Dev 2006. [DOI: 10.1021/op060210h] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Masaya Ikunaka
- Research & Development Center, Nagase & Co., Ltd. 2-2-3 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan, Faculty of Symbiotic Systems Science, Fukushima University, 1 Kanayagawa, Fukushima, Fukushima 960-1296, Japan, Medicinal Chemistry Group I, Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan, Department of Applied Biological Science, Faculty of Life Science, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama, Hiroshima 729-0292, Japan
| | - Shiro Kato
- Research & Development Center, Nagase & Co., Ltd. 2-2-3 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan, Faculty of Symbiotic Systems Science, Fukushima University, 1 Kanayagawa, Fukushima, Fukushima 960-1296, Japan, Medicinal Chemistry Group I, Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan, Department of Applied Biological Science, Faculty of Life Science, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama, Hiroshima 729-0292, Japan
| | - Daisuke Sugimori
- Research & Development Center, Nagase & Co., Ltd. 2-2-3 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan, Faculty of Symbiotic Systems Science, Fukushima University, 1 Kanayagawa, Fukushima, Fukushima 960-1296, Japan, Medicinal Chemistry Group I, Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan, Department of Applied Biological Science, Faculty of Life Science, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama, Hiroshima 729-0292, Japan
| | - Yasuhiro Yamada
- Research & Development Center, Nagase & Co., Ltd. 2-2-3 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan, Faculty of Symbiotic Systems Science, Fukushima University, 1 Kanayagawa, Fukushima, Fukushima 960-1296, Japan, Medicinal Chemistry Group I, Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan, Department of Applied Biological Science, Faculty of Life Science, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama, Hiroshima 729-0292, Japan
| |
Collapse
|
24
|
Zhu D, Mukherjee C, Hua L. ‘Green’ synthesis of important pharmaceutical building blocks: enzymatic access to enantiomerically pure α-chloroalcohols. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/j.tetasy.2005.08.037] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Sawa M, Tateishi H, Mizuno K, Harada H, Oue M, Tsujiuchi H, Furutani Y, Kato S. Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives. Bioorg Med Chem Lett 2005; 14:5963-6. [PMID: 15546708 DOI: 10.1016/j.bmcl.2004.09.054] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2004] [Revised: 09/14/2004] [Accepted: 09/17/2004] [Indexed: 11/20/2022]
Abstract
A series of tryptamine derivatives with modified sulfonamide were designed, synthesized, and evaluated for their ability to stimulate cAMP accumulation in CHO cells expressing the cloned human beta3-adrenergic receptor (AR). For this series of compounds, our objective was to symmetrize the alpha-position of the tryptamine moiety maintaining its activity and reducing the cost of production. Compound 11h, having m-aminobenzene, exhibited excellent agonistic activity for beta3-AR with excellent subtype selectivity.
Collapse
Affiliation(s)
- Masaaki Sawa
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd, 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S. Tryptamine-based human β3-adrenergic receptor agonists. Part 3: Improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett 2005; 15:1061-4. [PMID: 15686912 DOI: 10.1016/j.bmcl.2004.12.033] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2004] [Revised: 12/10/2004] [Accepted: 12/10/2004] [Indexed: 11/25/2022]
Abstract
The continued SAR investigation of tryptamine-based human beta(3)-adrenergic receptor (AR) agonists is reported. Prior efforts resulted in the identification of 2 as a potent beta(3)-AR agonist. Further modification of the left side arylsulfonamide portion in 2 provided compounds with good cell permeability, which have potent agonistic activity for beta(3)-AR. Cinnamylamine analog 16i exhibited an excellent agonistic profile in vitro and good oral bioavailability in rats.
Collapse
Affiliation(s)
- Masaaki Sawa
- Chemistry Research Loboratories, Dainippon Pharmaceutical Co., Ltd, Enoki 33-94, Suita, 564-0053, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Mizuno K, Sawa M, Harada H, Taoka I, Yamashita H, Oue M, Tsujiuchi H, Arai Y, Suzuki S, Furutani Y, Kato S. Discovery of 1,7-cyclized indoles as a new class of potent and highly selective human β3-adrenergic receptor agonists with high cell permeability. Bioorg Med Chem 2005; 13:855-68. [PMID: 15653351 DOI: 10.1016/j.bmc.2004.10.032] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2004] [Revised: 10/14/2004] [Accepted: 10/14/2004] [Indexed: 11/23/2022]
Abstract
The synthesis and evaluation of a novel series of 1,7-cyclized indole-based human adrenergic receptor (beta3-AR) agonists are reported. The synthesis of a variety of 1,7-cyclized indole part was accomplished by the Mitsunobu reaction or a ring closing metathesis (RCM) reaction. SAR studies revealed that expansion of the ring size resulted in considerable selectivity against the beta1- and beta2-ARs. Compound 26, an eight-membered ring analogue with a double bond on its 1,7-linker portion, was found to be a potent beta3-AR agonist (EC50 = 0.75 nM, IA = 90%) with extremely high selectivity for the beta3-AR over the beta1- and beta2-ARs.
Collapse
Affiliation(s)
- Kazuhiro Mizuno
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd, 33-94, Enoki, Suita 564-0053, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Nakajima Y, Hamashima H, Washizuka KI, Tomishima Y, Ohtake H, Imamura E, Miura T, Kayakiri H, Kato M. Discovery of a novel, potent and selective human β3-adrenergic receptor agonist. Bioorg Med Chem Lett 2005; 15:251-4. [PMID: 15603933 DOI: 10.1016/j.bmcl.2004.11.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2004] [Revised: 11/01/2004] [Accepted: 11/01/2004] [Indexed: 11/18/2022]
Abstract
The discovery of a novel, potent and selective beta(3)-adrenergic receptor (AR) agonist is described. SAR studies demonstrated the structural requirements for activity and selectivity. Compound 1c, which showed good beta(3)-AR activity and selectivity, was identified and pharmacokinetics were investigated.
Collapse
Affiliation(s)
- Yutaka Nakajima
- Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, 1-6, Kashima 2-Chome, Yodogawa-Ku, Osaka 532-8514, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
|
30
|
Mizuno K, Sawa M, Harada H, Tateishi H, Oue M, Tsujiuchi H, Furutani Y, Kato S. Tryptamine-based human β3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring. Bioorg Med Chem Lett 2004; 14:5959-62. [PMID: 15546707 DOI: 10.1016/j.bmcl.2004.10.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2004] [Revised: 10/13/2004] [Accepted: 10/13/2004] [Indexed: 11/21/2022]
Abstract
A series of tryptamine-based 2-thiophenesulfonamide derivatives were prepared and their agonistic activity for the beta-adrenergic receptors (ARs) was evaluated. Compound 54, containing 7-methanesulfonyloxy tryptamine, was found to be a highly potent beta3-AR agonist (EC50=0.21 nM, IA=97%) with excellent selectivity for the beta3-AR over the beta1- and beta2-ARs (210- and 86-fold, respectively).
Collapse
Affiliation(s)
- Kazuhiro Mizuno
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd, 33-94, Enoki, Suita 564-0053, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Monterde MI, Lombard M, Archelas A, Cronin A, Arand M, Furstoss R. Enzymatic transformations. Part 58: Enantioconvergent biohydrolysis of styrene oxide derivatives catalysed by the Solanum tuberosum epoxide hydrolase. ACTA ACUST UNITED AC 2004. [DOI: 10.1016/j.tetasy.2004.06.032] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Harada H, Fujii A, Odai O, Kato S. Process Development of a Scaleable Route to (2R)-[3-(2-Aminopropyl)-1H-indol-7-yloxy]-N,N-diethylacetamide: A Key Intermediate for AJ-9677, a Potent and Selective Human and Rat β3-Adrenergic Receptor Agonist. Org Process Res Dev 2004. [DOI: 10.1021/op0341869] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Hiroshi Harada
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan
| | - Akihito Fujii
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan
| | - Osamu Odai
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan
| | - Shiro Kato
- Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan
| |
Collapse
|